Figure 1. Efficacy outcomes per 2015... | American Society of Hematology

Figure 1.

Efficacy outcomes per 2015 International Working Group MDS/MPN response criteria19for patients with HMA-naïve CMML in part 2B. Efficacy was assessed at the end of cycles 1, 2, and 5 (C2D1, C3D1, and C6D1, respectively) or as clinically indicated. The first efficacy assessment time point at the end of cycle 1 was presented in the plot for all patients with data. If there is change in subsequent assessment from the previous one, the new efficacy outcome is indicated at the time of assessment. For calculation of duration of response, the first response date is any response observed regardless of CR, MR, or CB.

Efficacy outcomes per 2015 International Working Group MDS/MPN response criteria¹⁹ for patients with HMA-naïve CMML in part 2B. Efficacy was assessed at the end of cycles 1, 2, and 5 (C2D1, C3D1, and C6D1, respectively) or as clinically indicated. The first efficacy assessment time point at the end of cycle 1 was presented in the plot for all patients with data. If there is change in subsequent assessment from the previous one, the new efficacy outcome is indicated at the time of assessment. For calculation of duration of response, the first response date is any response observed regardless of CR, MR, or CB.

This Feature Is Available To Subscribers Only